RARE
NASDAQ
$28.53
Ultragenyx Pharmaceutical Inc (RARE)
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $52.53 (+84.12%)
Market Cap
$3.12B
Free Cash Flow Yield
-16.11%
Beta (5Y)
0.97
Price Chart
Valuation
Market Cap$3.12B
P/S4.71
P/B247.70
Profitability
Total Revenue (TTM)$670M
Gross Profit (TTM)-$188M
EBITDA-$527M
Profit Margin-90.9%
Operating Margin-102.2%
EPS-$6.28
Financial Health
Free Cash Flow Yield-16.11%
Growth & Risk
EPS 5Y CAGR+15.22%
Revenue 5Y CAGR+14.93%
FCF 5Y CAGR+15.66%
Beta (5Y)0.97
Sharpe Ratio0.39